Prostate Cancer - Results from #980

Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate. April 24, 2024

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer. April 24, 2024

Prostatectomy in oligometastatic prostate cancer: a call for high-quality evidence. April 24, 2024

Racial and ethnic disparities in prostate cancer screening following the 2018 US Preventive Services Task Force recommendation statement. April 24, 2024

A Systematic Review on the Impact of Quality Assurance Programs on Outcomes after Radical Prostatectomy. April 24, 2024

Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer. April 24, 2024

A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia. April 24, 2024

The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer. April 24, 2024

The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids. April 24, 2024

PGC-1α drives small cell neuroendocrine cancer progression towards an ASCL1-expressing subtype with increased mitochondrial capacity. April 24, 2024

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. April 24, 2024

Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer. April 23, 2024

Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition. April 23, 2024

The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression. April 23, 2024

A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers. April 23, 2024

Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways. April 23, 2024

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the April 23, 2024

Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies. April 23, 2024

Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years. April 23, 2024

Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. April 23, 2024

Page 50 of 1435